NASDAQ$PSNL
Personalis Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Personalis' Q2 2024 financial results were reported, featuring strong revenue growth.
Personalis reported a 35% year-over-year increase in total company revenue, driven by a 117% increase in revenue from biopharma business. The company also delivered 561 total molecular tests, a 66% increase compared to the prior quarter. They raised the full year revenue guidance for 2024.
- Total company revenue increased by 35% year-over-year, reaching $22.6 million.
- Revenue from pharma testing and services grew by 117% year-over-year, totaling $13.2 million.
- Net loss decreased by 47% year-over-year, amounting to $12.8 million.
- Delivered 561 total molecular tests, a 66% increase compared with the prior quarter.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$22.6M
Revenue by segment
Personalis · $18.2M total across 4 segments · Q3 2023
- Pharma tests and services$8M—43.8%
- Enterprise sales$7.81M—42.8%
- Population sequencing$2.4M—13.2%
- Other$38K—0.2%
Forward guidance
Personalis provided guidance for the third quarter and revised full year 2024 outlook.
Tailwinds
- Total company revenue is expected to be in the range of $21.0 to $22.0 million for Q3 2024.
- Revenue from pharma tests, enterprise sales, and other customers is expected to be in the range of $17.0 to $18.0 million for Q3 2024.
- Revenue from population sequencing is expected to be approximately $4.0 million for Q3 2024.
- Total company revenue is expected to be in the range of $79.0 to $81.0 million for the full year 2024, increased from $76.0 to $78.0 million.
- Revenue from pharma tests, enterprise sales, and all other customers is expected to be in the range of $71.0 to $73.0 million for the full year 2024, increased from prior guidance of $68.0 to $70.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro